Funding from Blood Cancer United can lead to scientific breakthroughs that will improve and save the lives of patients.
The Blood Cancer United Research Team oversees the organization's research strategy to support cutting-edge research for every type of blood cancer, including leukemia, lymphoma, and myeloma.
Take a look at all the currently active, extraordinary Blood Cancer United-funded research projects.
29 results
Refine Your Search
Board of Trustees of the Leland Stanford Junior University
This project is aimed at investigating a pre-clinical “off-the-shelf” CAR (chimeric antigen receptor) T-cell immunotherapy approach where the CAR cells are generated directly in the patient’s body. Importantly, this product will be a truly off the shelf therapy that is ready instantaneously and can be used repeatedly without the restriction of time-consuming manufacturing processes.
Project Term: July 1, 2020 - June 30, 2023
Dana-Farber Cancer Institute
Dr. Shipp and her colleague, Scott J. Rodig, MD, Ph.D., are mapping the immune microenvironment in classical Hodgkin lymphoma.
Project Term: July 1, 2020 - June 30, 2023
The Regents of the University of California, San Diego
Dr. Signer is investigating how the process of building defective proteins (inaccurate protein synthesis) plays a role in the development of a type of blood cancer called acute myeloid leukemia (AML) in the hopes of developing targeted therapies to treat this condition.
Project Term: July 1, 2020 - June 30, 2023
Cincinnati Children's Hospital Medical Center
Dr. Starczynowski is investigating the role and potential benefit of therapeutic targeting of a protein called UBE2N in acute myeloid leukemia (AML).
Project Term: July 1, 2020 - June 30, 2023
Fred Hutchinson Cancer Research Center
The most common cause of MDS is a genetic mutation occurring in blood cells that affects a process called “RNA splicing”. The most commonly mutated RNA splicing factor gene is called SF3B1. We now know that many patients with MDS carry mutations in SF3B1 but we do not know why these mutations cause disease. Dr. Bradley proposes to determine how mutations in SF3B1 cause MDS and potentially create new opportunities for treating this disease.
Project Term: July 1, 2020 - June 30, 2023
Who We Fund
Learn more about the inspiring blood cancer scientists we support—and leading biotech companies we partner with— who are working to find cures and help blood cancer patients live longer, better lives.
Research Grants
We award grants for studies that range from basic blood cancer research to pioneering clinical trials. For more than seventy years, Blood Cancer United support has been instrumental in the development of the vast majority of breakthroughs in blood cancer treatment.
Therapy Acceleration Program ®(TAP)
TAP is a mission-driven, strategic venture philanthropy initiative that seeks to accelerate the development of innovative blood cancer therapeutics and change the standard of care while also generating a return on investment for the Blood Cancer United mission. TAP collaborates with biotech companies to support the development of novel platforms, first-in-class assets addressing high unmet medical needs, emerging patient populations, and orphan indications.